Mr. Ehsan Agahi reports

ILLUMISOFT AND CAPGEMINI COLLABORATE TO ADVANCE HUMAN-SAFE FAR UVC PLATFORM FOR AIRBORNE PATHOGEN RISK REDUCTION IN HIGH-OCCUPANCY INDOOR ENVIRONMENTS

Illumisoft Lighting Corp. is developing its SaniLux 216 nanometre far ultraviolet C disinfection platform to enable the safe mitigation of airborne pathogen risk in high-occupancy indoor environments where people live, work, learn, travel and gather. Today, the company announced that it is taking steps to accelerate the platform's development.

To support the path to market for SaniLux, Illumisoft has entered into a strategic product development engagement with Capgemini to advance product development, industrial design, engineering architecture, manufacturing readiness and commercialization planning for the platform.

Capgemini is a global artificial-intelligence-powered business and technology transformation partner with operations across more than 50 countries and a worldwide team of approximately 420,000 team members. frog and Synapse, part of Capgemini, will carry out the engagement, bringing deep experience in innovation strategy, product design, connected technology engineering, manufacturing readiness and new product commercialization. Through this engagement, Capgemini will work alongside Illumisoft's technical leadership to help advance SaniLux from its current technology development stage toward a designed, engineered and manufacturable commercial product family for priority built environment applications.

Management commentary

"Airborne pathogen risk remains a meaningful challenge across health care, transportation, education, hospitality, commercial real estate and other high occupancy indoor environments," said Ehsan Agahi, executive chair of Illumisoft. "SaniLux is being developed to address that problem by enabling a potential continuous use far UVC disinfection platform for occupied spaces. Its objective is to turn SaniLux from a promising technology platform into a scalable and safe commercial product family for sectors where indoor air quality, infection prevention and operational continuity matter most. Working with Capgemini supports our efforts to advance the platform toward commercialization by complementing our semiconductor and lighting expertise with product design, engineering, manufacturing readiness and commercialization capabilities."

Capgemini commentary

"Far UVC has transformative potential for human health and well-being, aligning closely with frog's mission to better the human experience. We are proud to support Illumisoft in shaping and bringing this technology into the spaces where people live and work," said Ryan Starling, head of industrial design, West Coast, frog, part of Capgemini.

"We believe Illumisoft's far UVC technology represents an important scientific breakthrough. Together, we're focused on turning that innovation into a manufacturable, scalable and reliable product that can deliver real-world impact," said Kaethe Henning, director, consumer healthtech business of Synapse, part of Capgemini.

Market context

SaniLux is Illumisoft's far UVC device platform, designed for potential continuous use germicidal applications in occupied public and commercial spaces. Far UVC light at 216 nanometres is a narrow band of the ultraviolet spectrum that published research suggests may inactivate airborne pathogens without the skin and eye hazards associated with conventional germicidal UV wavelengths. This characteristic is central to Illumisoft's design objective of enabling continuous use in occupied spaces.

The company is developing SaniLux for settings where managing the risk of airborne infection is a critical operational priority, including health care facilities, long-term-care settings, transportation hubs, hospitality venues, educational institutions, commercial real estate and major entertainment venues. These are settings where conventional germicidal UV solutions are generally not suitable for continuous use in the presence of occupants and where the company believes a safe, continuous use alternative could address a meaningful unmet need.

These sectors often share a common operating profile: high occupant density, prolonged exposure times, and meaningful operational, financial and reputational costs associated with airborne disease transmission. Recent public health events in enclosed, high occupancy environments have increased industry and regulatory focus on engineered indoor air quality interventions. At the same time, evolving construction, health care and infection prevention standards are increasing attention on ultraviolet germicidal technologies as part of broader indoor air quality and risk reduction strategies.

Management estimates, based on publicly available industry research, that the global market for ultraviolet disinfection technologies is in the multibillion-dollar range and is growing at a double -igit compound annual rate, driven by sustained indoor air quality investment, standards evolution and operator level recognition of the cost of inaction. Illumisoft is developing SaniLux to address applications where continuous use, occupied space deployment is required and where many conventional ultraviolet germicidal solutions are not designed to operate.

Scope of the engagement

The engagement is expected to support a structured product development program for SaniLux, with work streams focused on market and technology assessment, supply chain and manufacturing review, industrial design, engineering architecture, form factor development, prototyping, minimum viable product planning, pilot readiness, third party study support, and new product introduction planning. The objective is to provide Illumisoft with a disciplined product development pathway that can help translate the SaniLux technology platform into commercial configurations suitable for priority-built environment applications.

About Illumisoft Lighting Corp.

Illumisoft is a photonic disinfection and lighting technology company focused on the design, development and commercialization of advanced ultraviolet germicidal solutions for health care, commercial, transportation, hospitality and other built environment markets. The company's product portfolio includes SaniLume, an upper room germicidal UV platform; SaniLux, a 216-nanometre far UVC platform; and ECOWing LED commercial lighting. Illumisoft trades on the TSX Venture Exchange under the symbol UVC.

We seek Safe Harbor.